The
mammalian target of rapamycin (mTOR) is a signaling
kinase of the
phosphatidylinositol 3-kinase/
protein kinase B (also known as Akt) signaling pathway that mediates cell growth and metabolism. Dysregulation of the mTOR pathway creates a favorable environment for the development and progression of many
cancers, including
breast cancer, and is associated with the development of resistance to endocrine
therapy and to the anti-human
epidermal growth factor receptor-2 (HER2)
monoclonal antibody trastuzumab. Therefore, the addition of
mTOR inhibitors to conventional
breast cancer therapy has the potential to enhance therapeutic efficacy and/or overcome innate or acquired resistance.
Everolimus, an mTOR inhibitor with demonstrated preclinical activity against
breast cancer cell lines, has been shown to reverse Akt-induced resistance to hormonal
therapy and
trastuzumab. Phase I-II clinical trials have demonstrated that
everolimus has promising clinical activity in women with HER2-positive, HER2-negative, and
estrogen receptor-positive
breast cancer when combined with HER2-targeted
therapy, cytotoxic
chemotherapy, and hormonal
therapy, respectively.
Everolimus is generally well tolerated; hematologic abnormalities and
stomatitis are most common adverse events when this
drug is combined with cytotoxic
chemotherapy. Based on these promising results,
everolimus is currently under evaluation in a series of phase III
Breast Cancer Trials of Oral
Everolimus (
BOLERO) trials of women with HER2-positive and
estrogen receptor-positive
breast cancer. Results of these trials will help to establish the role of
everolimus in the treatment of clinically important
breast cancer subtypes.